 Dithi Banerjee
Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Syncytial Virus, Human | 2 | 2019 | 18 | 1.570 |
Why?
| | Influenza B virus | 2 | 2019 | 16 | 1.570 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2019 | 12 | 1.560 |
Why?
| | Influenza A virus | 2 | 2019 | 18 | 1.560 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2019 | 37 | 1.540 |
Why?
| | Influenza, Human | 2 | 2019 | 32 | 1.530 |
Why?
| | Nasopharynx | 4 | 2021 | 23 | 1.300 |
Why?
| | Pharyngitis | 1 | 2020 | 13 | 0.870 |
Why?
| | Streptococcal Infections | 1 | 2020 | 20 | 0.850 |
Why?
| | Cryptococcus neoformans | 2 | 2016 | 2 | 0.820 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 3 | 0.680 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 3 | 0.680 |
Why?
| | Glucose | 1 | 2016 | 18 | 0.670 |
Why?
| | Humans | 14 | 2021 | 5491 | 0.660 |
Why?
| | Child | 9 | 2021 | 2540 | 0.570 |
Why?
| | Nucleotides | 1 | 2014 | 1 | 0.570 |
Why?
| | Amphotericin B | 1 | 2014 | 2 | 0.570 |
Why?
| | Antifungal Agents | 1 | 2014 | 13 | 0.560 |
Why?
| | Antibodies, Viral | 3 | 2021 | 25 | 0.510 |
Why?
| | Adult | 6 | 2021 | 1033 | 0.510 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2021 | 36 | 0.460 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 145 | 0.450 |
Why?
| | Picornaviridae Infections | 2 | 2021 | 18 | 0.420 |
Why?
| | Middle Aged | 5 | 2021 | 551 | 0.380 |
Why?
| | Infant | 7 | 2021 | 1311 | 0.380 |
Why?
| | Young Adult | 5 | 2021 | 550 | 0.370 |
Why?
| | Spike Glycoprotein, Coronavirus | 3 | 2021 | 15 | 0.350 |
Why?
| | Adolescent | 6 | 2021 | 1869 | 0.320 |
Why?
| | Cryptococcosis | 2 | 2016 | 2 | 0.310 |
Why?
| | Female | 7 | 2021 | 3230 | 0.300 |
Why?
| | Aged | 3 | 2021 | 292 | 0.300 |
Why?
| | Child, Preschool | 5 | 2021 | 1438 | 0.300 |
Why?
| | Retrospective Studies | 2 | 2019 | 1041 | 0.290 |
Why?
| | Prospective Studies | 3 | 2021 | 444 | 0.290 |
Why?
| | Parechovirus | 2 | 2021 | 17 | 0.280 |
Why?
| | Male | 6 | 2021 | 3158 | 0.270 |
Why?
| | Aged, 80 and over | 2 | 2021 | 112 | 0.260 |
Why?
| | Saliva | 1 | 2021 | 9 | 0.240 |
Why?
| | Specimen Handling | 1 | 2021 | 17 | 0.240 |
Why?
| | Immunity, Humoral | 1 | 2021 | 5 | 0.240 |
Why?
| | Nasal Mucosa | 1 | 2021 | 8 | 0.240 |
Why?
| | Central Nervous System Infections | 1 | 2021 | 5 | 0.230 |
Why?
| | Enterovirus | 1 | 2021 | 8 | 0.230 |
Why?
| | Enterobacteriaceae | 1 | 2021 | 5 | 0.230 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2021 | 11 | 0.230 |
Why?
| | Cephalosporins | 1 | 2021 | 16 | 0.230 |
Why?
| | Enterovirus Infections | 1 | 2021 | 28 | 0.220 |
Why?
| | Quebec | 1 | 2020 | 4 | 0.220 |
Why?
| | Pharynx | 1 | 2020 | 7 | 0.220 |
Why?
| | Canada | 1 | 2020 | 31 | 0.220 |
Why?
| | Streptococcus pyogenes | 1 | 2020 | 14 | 0.220 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 4 | 0.220 |
Why?
| | Rhinovirus | 1 | 2020 | 6 | 0.220 |
Why?
| | Virus Diseases | 1 | 2020 | 12 | 0.220 |
Why?
| | RNA, Messenger | 2 | 2021 | 180 | 0.210 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 41 | 0.210 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2019 | 3 | 0.200 |
Why?
| | Respiratory Tract Infections | 1 | 2020 | 54 | 0.200 |
Why?
| | Communicable Diseases, Emerging | 1 | 2019 | 3 | 0.200 |
Why?
| | Microbial Sensitivity Tests | 2 | 2021 | 34 | 0.200 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 215 | 0.190 |
Why?
| | Ribosomes | 1 | 2016 | 1 | 0.170 |
Why?
| | Ribosomal Proteins | 1 | 2016 | 4 | 0.170 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2016 | 5 | 0.170 |
Why?
| | RNA Stability | 1 | 2016 | 4 | 0.170 |
Why?
| | Fungal Proteins | 1 | 2016 | 11 | 0.170 |
Why?
| | Aspergillus fumigatus | 1 | 2014 | 1 | 0.140 |
Why?
| | Flucytosine | 1 | 2014 | 1 | 0.140 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 5 | 0.140 |
Why?
| | Candida albicans | 1 | 2014 | 4 | 0.140 |
Why?
| | HIV Infections | 1 | 2014 | 135 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2021 | 144 | 0.110 |
Why?
| | Missouri | 2 | 2021 | 86 | 0.110 |
Why?
| | Infant, Newborn | 2 | 2021 | 843 | 0.080 |
Why?
| | Immunity, Cellular | 1 | 2021 | 9 | 0.060 |
Why?
| | Viral Load | 1 | 2021 | 19 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2021 | 6 | 0.060 |
Why?
| | Antibody Specificity | 1 | 2021 | 8 | 0.060 |
Why?
| | Cross Reactions | 1 | 2021 | 7 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2021 | 17 | 0.060 |
Why?
| | Epitopes | 1 | 2021 | 15 | 0.060 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 8 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2021 | 33 | 0.060 |
Why?
| | Transcriptome | 1 | 2021 | 32 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2021 | 17 | 0.060 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.060 |
Why?
| | Kansas | 1 | 2021 | 46 | 0.060 |
Why?
| | Immunoglobulin G | 1 | 2021 | 34 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2021 | 115 | 0.060 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 28 | 0.060 |
Why?
| | Biomarkers | 1 | 2021 | 114 | 0.060 |
Why?
| | Mouth | 1 | 2020 | 3 | 0.060 |
Why?
| | Age Factors | 1 | 2021 | 221 | 0.050 |
Why?
| | DNA, Viral | 1 | 2020 | 13 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 23 | 0.050 |
Why?
| | Postoperative Care | 1 | 2020 | 28 | 0.050 |
Why?
| | Prevalence | 1 | 2020 | 128 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2020 | 118 | 0.050 |
Why?
| | Prognosis | 1 | 2020 | 175 | 0.050 |
Why?
| | Risk Assessment | 1 | 2020 | 126 | 0.050 |
Why?
| | Seasons | 1 | 2019 | 13 | 0.050 |
Why?
| | Phylogeny | 1 | 2019 | 15 | 0.050 |
Why?
| | Fever | 1 | 2019 | 30 | 0.050 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 83 | 0.050 |
Why?
| | Genotype | 1 | 2019 | 277 | 0.050 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|